Stryker Co. (NYSE:SYK) Shares Acquired by FSM Wealth Advisors LLC

FSM Wealth Advisors LLC lifted its holdings in shares of Stryker Co. (NYSE:SYK) by 2.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,888 shares of the medical technology company’s stock after buying an additional 52 shares during the period. FSM Wealth Advisors LLC’s holdings in Stryker were worth $682,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of SYK. Koshinski Asset Management Inc. acquired a new stake in Stryker in the 1st quarter valued at about $795,000. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Stryker by 43.1% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 18,491 shares of the medical technology company’s stock worth $6,617,000 after acquiring an additional 5,565 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S raised its position in shares of Stryker by 38.5% during the first quarter. BI Asset Management Fondsmaeglerselskab A S now owns 19,796 shares of the medical technology company’s stock worth $7,084,000 after purchasing an additional 5,502 shares during the period. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Stryker by 78.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 133,020 shares of the medical technology company’s stock valued at $45,260,000 after purchasing an additional 58,673 shares during the last quarter. Finally, M&G Plc acquired a new position in shares of Stryker in the 1st quarter valued at $11,534,000. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 600 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total value of $213,000.00. Following the completion of the sale, the insider now directly owns 9,069 shares in the company, valued at approximately $3,219,495. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Viju Menon sold 600 shares of the company’s stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $355.00, for a total transaction of $213,000.00. Following the transaction, the insider now owns 9,069 shares of the company’s stock, valued at $3,219,495. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, VP M Kathryn Fink sold 2,121 shares of Stryker stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $370.00, for a total value of $784,770.00. Following the completion of the sale, the vice president now owns 10,042 shares of the company’s stock, valued at approximately $3,715,540. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,068 shares of company stock valued at $3,693,972. 5.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several analysts have issued reports on the company. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and set a $420.00 price target (up previously from $380.00) on shares of Stryker in a report on Wednesday, October 30th. Wolfe Research began coverage on shares of Stryker in a research note on Tuesday, September 10th. They issued an “outperform” rating and a $405.00 price objective for the company. Stifel Nicolaus cut their target price on shares of Stryker from $375.00 to $365.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Finally, Morgan Stanley raised their target price on Stryker from $345.00 to $350.00 and gave the stock an “equal weight” rating in a research report on Monday, July 15th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $393.65.

Stryker Trading Down 0.1 %

Shares of NYSE:SYK opened at $366.90 on Tuesday. The stock has a market capitalization of $139.87 billion, a PE ratio of 39.32, a P/E/G ratio of 2.77 and a beta of 0.91. The firm has a fifty day moving average price of $360.43 and a 200 day moving average price of $344.64. Stryker Co. has a 1 year low of $266.93 and a 1 year high of $374.63. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66.

Stryker (NYSE:SYK) last released its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analyst estimates of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business’s revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.46 EPS. Analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were issued a dividend of $0.80 per share. This represents a $3.20 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend was Monday, September 30th. Stryker’s payout ratio is 34.30%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.